Skip to the main content

Original scientific paper

https://doi.org/10.20471/acc.2019.58.01.03

Expression of MUC2 Glycoprotein Antibody and Vascular Endothelial Growth Factor in Barrett’s Mucosa

Melanija Ražov Radas orcid id orcid.org/0000-0003-4530-4350 ; Division of Gastroenterology, Department of Internal Medicine, Zadar General Hospital, Zadar, Croatia


Full text: english pdf 297 Kb

page 23-27

downloads: 406

cite


Abstract

Higher expression of the mucin 2 (MUC2) glycoprotein and vascular endothelial growth factor (VEGF) in Barrett’s mucosa may be associated with a higher risk of esophageal adenocarcinoma development. Thirty-six patients diagnosed with Barrett’s esophagus (BE), short-segment,
were included in the study due to unsuccessful treatment with proton pump inhibitors. The diagnosis was confirmed by histopathologic analysis of the tissue obtained by esophagogastric junction biopsy. Expression of MUC2 and VEGF was determined by immunohistochemistry. We found four patients in early stage of adenocarcinoma and 32 patients with BE; five of them had indication for argon plasma coagulation treatment, one for radiofrequency ablation and one for endoscopic mucosal resection; 25 patients were treated with proton pump inhibitors. Regression of BE occurred in 25 (69.44%)
patients. MUC2 positivity is unique for goblet cells in patients with BE, but it is not the only marker. VEGF is an indicator of angiogenesis in the mucosa of patients with BE and adenocarcinoma.

Keywords

Barrett esophagus; Mucin 2; Vascular endothelial growth factor; Proton pump inhibitors; Goblet cells

Hrčak ID:

220521

URI

https://hrcak.srce.hr/220521

Publication date:

1.3.2019.

Article data in other languages: croatian

Visits: 1.351 *